Plerixafor Dose Escalation

DRUG2 trials

Sponsors

Seattle Children's Hospital, Hospital Israelita Albert Einstein

Conditions

ALLAMLAcute Leukemia of Ambiguous LineageRelapsed/Refractory ALLRelapsed/Refractory AMLSecondary AML/MDSSickle Cell Disease

Phase 1

POETIC Plerixafor as a Chemosensitizing Agent for Relapsed Acute Leukemia and MDS in Pediatric Patients

CompletedNCT01319864

Seattle Children's HospitalAcute Leukemia of Ambiguous Lineage, ALL, AML +3

Start: 2011-03-31End: 2016-06-28Updated: 2018-09-07

STEM CELL MOBILIZATION WITH HIGH-DOSE PLERIXAFOR IN PATIENTS WITH SICKLE CELL DISEASE

Not yet recruitingNCT07341022

Hospital Israelita Albert EinsteinSickle Cell Disease

Start: 2026-06-01End: 2028-06-30Target: 12Updated: 2026-01-14

Related Papers

Chemosensitization and Mobilization Of AML/ALL/MDS With Plerixafor (AMD 3100), a CXCR4 Antagonist: A Phase I Study Of Plerixafor + Cytarabine and Etoposide In Pediatric Patients With Acute Leukemia and MDS

Blood2013-11-155 citations